# The Efficacy and Safety of Sonrotoclax, Zanubrutinib Combined With Obinutuzumab in MCL

> **NCT07548255** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 28 (estimated)

## Conditions studied

- Intermediate-to-High-Risk Mantle Cell Lymphoma
- the Efficacy and Safety

## Interventions

- **DRUG:** Sonrotoclax, Zanubrutinib Combined with Obinutuzumab

## Key facts

- **NCT ID:** NCT07548255
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-20
- **Primary completion:** 2029-03-01
- **Final completion:** 2029-03-01
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07548255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07548255, "The Efficacy and Safety of Sonrotoclax, Zanubrutinib Combined With Obinutuzumab in MCL". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07548255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*